{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-429647","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2026-10-23T14:31:29+00:00","discovered_at":"2026-10-23T14:33:00.098013+00:00","generated_at":"2026-10-23T14:33:15.696493+00:00","sec_items":["1.01","5.03","1.02","2.01","3.02","5.02","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Bolt Biotherapeutics acquires Prana in reverse merger; raises $120M PIPE, Prana holders to own 51.7% post-financing","bullets":["Bolt acquired Prana on Oct. 23, 2026; Prana holders received 430,746 BOLT shares plus 16,360.929 Series D preferred shares convertible into 1,000 common each.","Pre-transaction Bolt holders fall to ~11.8% pre-financing and ~6.9% post-financing; Prana holders ~88.2% then ~51.7%; PIPE investors ~41.4%.","$120M PIPE sale of 13,995.311 Series D preferred shares plus warrants for 50% more, expected to close Oct. 26, 2026; full warrant exercise would add ~$60M gross.","Series D pays as-if-converted dividends, has no general voting rights but must approve specified actions; votes cover conversion, Nasdaq proposals, charter amendment, 1:2-1:12 reverse split.","Lease termination triggers $4.5M payment to HCP LS Redwood City; Dr. Sheila Gujrathi joins board and becomes Chief Strategy Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-429647","json":"https://secwatch.observer/filing/0001193125-26-429647.json","markdown":"https://secwatch.observer/filing/0001193125-26-429647.md","text":"https://secwatch.observer/filing/0001193125-26-429647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526429647/0001193125-26-429647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526429647/bolt-20261023.htm"},"model":{"generated_by":"deepseek-v4.1-flash:cloud@v2","generated_at":"2026-10-23T14:33:15.696493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0df65b23df","claim":"Sheila Gujrathi was appointed as Class II director at Bolt Biotherapeutics, Inc..","evidence_excerpt":"In accordance with the Merger Agreement, on October 23, 2026, effective immediately after the First Effective Time, Dr. Sheila Gujrathi was appointed to the Board as a Class II director of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526429647/0001193125-26-429647-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}